Anti-obesity Effect of Koji-extracted Beverage Fermented With Pediococcus Pentosaceus LP28
NCT ID: NCT02050555
Last Updated: 2014-08-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
50 participants
INTERVENTIONAL
2013-12-31
2014-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prebiotic Fiber as a Modifier of Satiety Hormones and Body Weight in Overweight and Obese Adults
NCT00522353
The Effect of a Bifidobacterium and Polydextrose on Body Fat Mass
NCT01978691
Assessing Fermentability of a Dietary Fiber
NCT01497249
Effect of Coadministration of Ume Paste (Prunus Mume) and Ginger Powder
NCT02213549
Stevia Extract and Glucose Homeostasis
NCT04335565
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Koji-extracted beverage
100ml/day for 12 weeks
Placebo
Koji-extracted beverage fermented with LP28
100ml/day for 12 weeks. 1x10\^11 cells (LP28)/day
Koji-extracted beverage fermented with Pediococcus pentosaceus LP28
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Koji-extracted beverage fermented with Pediococcus pentosaceus LP28
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Pregnant or nursing a child
* Participation in any clinical trial within 90 days of the commencement of the trial
* Renal or hepatic dysfunction
* Heart disease
* History of severe disease and/or major surgery
20 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Marukome Co., Ltd.
UNKNOWN
Hiroshima University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fumiko Higashikawa
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fumiko Higashikawa, PhD
Role: PRINCIPAL_INVESTIGATOR
Hiroshima University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hiroshima University
Hiroshima, Hiroshima, Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
eki-867
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.